Voyager insider plans sale of 3,525 shares

Voyager Therapeutics has a planned sale of 3,525 shares of its common stock under Rule 144.

Rhea-AI Filing Summary

Voyager Therapeutics has a planned sale of 3,525 shares of its common stock under Rule 144. The shares have an aggregate market value of $13,552.57 and are to be sold through Fidelity Brokerage Services on NASDAQ around 02/10/2026.

The seller acquired these 3,525 common shares on 02/09/2026 through restricted stock vesting as compensation from the issuer. The filing notes that 55,600,084 shares of common stock were outstanding, providing context for the size of this transaction.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Voyager Therapeutics (VYGR) Form 144 filing report?

The Form 144 reports an intended sale of 3,525 Voyager Therapeutics common shares. These shares, worth $13,552.57, were acquired through restricted stock vesting as compensation and are planned to be sold on NASDAQ through Fidelity Brokerage Services around February 10, 2026.

How many Voyager Therapeutics (VYGR) shares are planned to be sold?

The filing covers a planned sale of 3,525 Voyager Therapeutics common shares. The aggregate market value of this block is reported as $13,552.57, with the transaction to be executed through Fidelity Brokerage Services on NASDAQ around February 10, 2026.

How were the Voyager Therapeutics (VYGR) shares in this Form 144 acquired?

The 3,525 Voyager Therapeutics shares were acquired on February 9, 2026, via restricted stock vesting. The filing classifies the nature of the acquisition as compensation from the issuer, rather than a cash purchase in the open market or via a gift transaction.

What is the market value of the Voyager Therapeutics (VYGR) shares being sold?

The Form 144 lists an aggregate market value of $13,552.57 for the 3,525 Voyager Therapeutics common shares. This amount reflects the value at the time of the filing and is associated with the planned NASDAQ sale through Fidelity Brokerage Services LLC.

How many Voyager Therapeutics (VYGR) shares were outstanding in this filing?

The document states that 55,600,084 Voyager Therapeutics common shares were outstanding. This figure provides context for the planned sale of 3,525 shares, showing the relative size of the proposed disposition compared with the company’s total common shares outstanding.

Which broker and exchange are used for this Voyager Therapeutics (VYGR) share sale?

The planned sale will be executed through Fidelity Brokerage Services LLC. The Form 144 lists NASDAQ as the securities exchange where the 3,525 Voyager Therapeutics common shares are expected to be sold around February 10, 2026, subject to normal trading conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 03:11 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001944011
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Voyager Therapeutics, Inc.
SEC File Number	001-37625
Address of Issuer	75 HAYDEN AVENUE LEXINGTON MASSACHUSETTS 02421
Phone	857-259-5340
Name of Person for Whose Account the Securities are To Be Sold	Carter Todd Alfred
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3525	13552.57	55600084	02/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/09/2026	Restricted Stock Vesting	Issuer			3525	02/09/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	02/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Todd Carter
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)